MAPT and Alzheimer disease: It is an ongoing Phase 3, double-blind, placebo-controlled clinical trial designed to assess the safety and efficacy of donanemab in individuals with early symptomatic AD, specifically those in the prodromal stage or with mild dementia due to AD, who exhibit brain tau pathology.